ARTIFICIAL INTELLIGENCE IN PHARMACEUTICALS

[1]Akanksha Rajoriya, [2]Mukul Yadav, [3]Dr. Ravi Shekhar
[1]M.Pharm Scholar, Institute of Pharmacy and Paramedical Sciences, Dr. Bhim Rao Ambedkar University, Agra
[2]Assistant Professor, Institute of Pharmacy and Paramedical Sciences, Dr. Bhim Rao Ambedkar University, Agra
[3]Assistant Professor, Institute of Pharmacy and Paramedical Sciences, Dr. Bhim Rao Ambedkar University, Agra

Abstract: Artificial Intelligence is continuously changing the landscape of pharmaceutical sciences by solving major issues related to traditional drug discovery and development practices like high cost, long duration and low success rate. This review presents an encompassing overview of Artificial Intelligence applications from drug design and development to delivery in the pharmaceutical pipeline, following a systematic review of recent literature (2020-2025) from major scientific databases followed by thematic analysis and quality assessment. Artificial intelligence techniques (such as machine learning, deep learning, and big data analytics) have significantly improved the drug discovery process because they enable quick screening of enormous molecular datasets, precise prediction of pharmacodynamic interactions, and effective lead optimization. Artificial Intelligence also helps to develop personalized medicine that integrates genomics, proteomics, and clinical data to create custom-tailored therapies for patients. According to the review, creating novel pharmacological indications for already-approved medications can be done quickly and affordably through artificial intelligence-based drug repurposing. The report also suggests how Artificial Intelligence is being implemented in drug delivery systems, pharmacovigilance, clinical trials, healthcare services, etc. to improve patient outcomes and efficiency. Such Artificial Intelligence has a huge potential with great possibilities; however, there are many challenges to its implementation. For instance, bias in data, lack of transparency, regulatory challenges, concerns over data privacy and security, etc. Such challenges highlight the need for strong governance frameworks as well as the need for explainable Artificial Intelligence. Overall, Artificial Intelligence is evolving into an engine of innovation in pharmaceuticals- creating a future of more efficient, accurate, and personalized healthcare solutions. It also illuminates important research gaps and future directions for sustainable integration of these technologies in the healthcare system.

Index Terms- **Artificial Intelligence, Drug Discovery, Drug Repurposing, Machine Learning, Deep Learning, Pharmaceutical Pipeline.**

1. INTRODUCTION

One of the biggest developments influencing contemporary pharmaceutical sciences is artificial intelligence, or AI. As pharmaceutical drug discovery and development processes grow more complex, traditional pharmacology approaches are usually costly, take a lot of time, and ultimately fail over 90% of the time[1-3]. Drug research and development processes have made use of a variety of AI and machine learning methods, as shown in **(Table 1)**. AI offers innovative solutions using methods like machine learning, deep learning, and big data analytics to make all aspects of drug process more efficient, and with increased accuracy, and decreased costs[4-6]. From a data standpoint, AI can screen many millions of molecules, can predict the interactions with targets using high throughput screening, and can even help redesign novel compounds, which helps to increase expected success rate[2, 6-8]. Additionally, AI can support drug repurposing, which is critical to finding novel use for currently available medicines, especially when responding to emergent diseases[1, 9, 10]. Also, AI is essential to both drug delivery and personalized medicine by combining genomic, proteomic and patient files to provide patient/citizen specific medicines that improve drug release[5, 11]. Such applications can provide new dosage forms such as nano-medicine, or more advanced dosage forms such as 3D printed system[5, 7, 12].

Table 1: List of AI tools employed in drug discovery and development.

Tools	Details	Websites	References
Alpha Fold	Alpha Fold Forecasts Protein 3D Structures	https://deepmind.com/blog/ alphafold	(13-15)
Deep Chem	A Python-based AI system is used by the Deep Chem MLP model to identify a promising candidate for drug discovery.	https://github.com/deepchem/ deepchem	[16, 17]
Hit Dexter	Predicting compounds that could react to biochemical tests using the Hit Dexter machine learning approach	http://hitdexter2.zbh.uni hamburg.de	(16-18)
Chemputer	Chemputer aids in reporting chemical synthesis processes in a uniform format	https://zenodo.org/ record/1481731	[17]
Deep Tox	Deep Tox software that forecasts the toxicity of 12,000 medications	www.bioinf.jku.at/research/ DeepTox	[16, 17, 19]
ORGANIC	An instrument for generating molecules with the characteristics that are ideal	https://github.com/aspuru guzik-group/ORGANIC	[20, 21]
Neural graph fingerprint	Aids in predicting attributes of new compounds	https://github.com/HIPS/ neural-fingerprint	[20, 22, 23]

AI will also play a significant part in clinical trials and manufacturing by promoting operational efficiency and minimizing human errors across various sectors of production[4, 6, 24]. In pharmacy practice, AI can also improve medication reconciliation, workflows and ultimately patient care[25-27]. Despite all the good AI has provided and can promise, current challenges with AI and pharmaceuticals still exist, particularly with respect to privacy, transparency, regulations and ethics[9, 11, 28]. Although, the governance of AI and its practical use in pharmaceuticals, has explicitly been identified as a priority governance target, to assure the appropriate and secure application of AI[9, 29, 30].

In conclusion, there has been a rapid evolution of AI from a supporting tool to an engine of pharmaceutical innovation. AI also has the potential to create value from the knowledge economy throughout the pipeline from discovery to delivery while also facilitating a more personalized approach to health care. This review will elaborate on where and how AI is being used, note some challenges associated with its use, and finalize with some future directions which may shape and redefine drug development and the overall patient experience with their care.

2. METHODOLOGY

The most significant phase in the review procedure is the recognition, organizing and extracting of latest and most relevant literature on the use of AI in pharmaceuticals. This process provides a comprehensive approach regarding updated evolution, applications, serious problems and their solutions, future directions, and the scope of the pharmaceutical industry. Some of the major steps are as follows:

2.1 Literature Search

An exhaustive literature search was performed using Google Scholar, Scopus, PubMed databases with keywords such as ‘Artificial Intelligence in Pharmaceutical Sciences’, ‘AI in Drug Delivery’, ‘AI in Pharmaceutical Products’, ‘AI in Drug Discovery and Personalized Medicine’, ‘AI in Pharmacy’, ‘AI and ML applications in Pharmaceuticals', 'AI in Pharmaceutical Manufacturing', 'Governance of AI in Pharmaceutical Industry'. Boolean operators such as AND, OR, and NOT were applied to elevate the search outcomes and secure admissible studies.

2.2 Selection Process

The review targeted on studies published in the English language between 2020 and 2025. From multidisciplinary databases a wide range of articles were fetched and studies were examined based on titles, abstracts and full texts, and duplicates or irrelevant works were not included in order to preserve authenticity and relevance of the review. For final inclusion, only those studies which were directly associated with pharmaceutical research and applications were considered.

2.3 Data Extraction

Studies were conducted on various aspects of AI in pharmaceuticals such as in clinical trial, manufacturing, process optimization, quality assurance, regulatory compliance, supply chain, pharmacy practice, patient care, drug repurposing, tailored treatment plans and finally segregated data were evaluated on the basis of abstracts given in their respective publications which were carefully reviewed to examine applicability to the topic. The extracted data were systematically arranged into categories to aid thematic analysis. This process allowed distinct comparison of how AI has been practiced throughout different phases of the development of pharmaceuticals.

2.4 Data Analysis and Synthesis

The information obtained from the extracted data were thematically categorized into different core areas. All the findings from various studies were integrated and more attention was given to common trends, applications, technological evolution, and upcoming challenges. To identify similarities and differences in approaches described by various authors deep analysis were also performed. Through this process, existing knowledge were not only summarized but also potential gaps and future directions for research in AI- driven pharmaceutical sciences were identified by the review.

2.5 Quality Assessment

The credibility and methodological strictness were followed by using peer-reviewed articles from reputed journals and articles from recognized databases. Publications deprived of direct relevance and methodological specifications towards pharmaceutical applications were excluded. The authenticity, objectivity and integrity of the review findings were maintained by this step of quality assessment.

3. APPLICATIONS

3.1 Drug Discovery and Development:

AI tools can screen various data types such as clinical data, physiological data, and genetic profile to recognize important pharmacological sites[2, 11, 26]. On the basis of rapid determination of RNA (Ribonucleic acid) and DNA (Deoxyribonucleic acid) by sequencing and biological factors, AI facilitates drug compound segregation with a consistent success rate in drug development[1, 2, 31]. By utilizing machine learning algorithms, AI has become a potent tool for finding new drugs. ML can analyze large and complex set of data and predict promising drug candidates with increased efficiency and accuracy[5, 24, 32]. The major step during drug discovery is identification of appropriate drug targets to design molecular mechanisms to achieve therapeutic effects[2, 4, 33]. After selecting potential drug candidates, lead optimization is necessary to enhance pharmacokinetic properties, potency and selectivity[3, 7, 34]. Traditional lead optimization processes were very time consuming as well as expensive, AI offers data-driven and more systematic strategy to lead optimization, enabling more accurate and efficient prediction of a novel compound's drug-like qualities[5, 9, 35]. The global pharmaceutical companies have been implementing AI in the development of new drugs as elucidated in **table 2.**

Table 2: Leveraging of AI by global pharmaceutical firms for the development and discovery of new drugs.

ESTABLISHED PHARMA GROUPS	IMPLEMENTATION OF AI
NOVARTIS	Seeks to expand AI over a ten-year period to enhance access, prices, and wellness results in collaboration with Microsoft and NVIDIA.
BAYER	Collaborated with Exscientia to investigate artificial intelligence-based minute compound drug detection in order to expedite the identification of novel therapeutic prospects.
SANOFI	Development of artificial intelligence (AI) platform- “Plai” for pharmaceutical research, clinical trials and manufacturing.
ASTRAZENECA	Associated with Oncoshot in 2021 to use BenevolentAI to find objects and AI to link patients to clinical study.
PFIZER	Generates innovative medications, such as PAXLOVID, an oral COVID-19 therapy authorized in 2022, using IBM's supercomputing and artificial intelligence since 2020.
BRISTOL MYERS SQUIBB	Collaborated with Exscientia to find minute compound drugs for immunology and cancer using artificial intelligence.
JANSEEN	Investigating the implementation of AI in production, clinical studies, medication research, and medical condition identification.

3.2 AI and Tailored Therapy:

AI tools are being utilized in predicting the response of various patients to specific drugs. It can be done by analyzing vast amount of biomedical data such as genetic profile, metabolism etc. to find possible biomarkers connected to medication safety and efficacy[1-3, 7]. Customized or tailored medications are appropriate therapies as they tailored according to individual patient’s unique characteristics which suits their lifestyle, medical history, genetic makeup, lowering the possibility of negative consequences and enhancing general patient compliance[2, 9, 24]. Personalized medicines can be adjusted in real time, ensuring maximum efficacy and reducing adverse effects and facilitating patients' adherence to recommended therapies[4, 25, 36, 37]. There are various AI platforms which assist medical professionals in creating customized treatment plans and facilitate them to serve remotely through AI powered apps in which patients can select their preferences and accordingly healthcare team can design their treatment plans and monitor the patient’s adherence to medication[5, 11, 26, 29]. **Figure 1** aptly summarizes the role of AI in the personalized therapy.



Figure 1: AI's function in gathering and evaluating patient data for personalized treatment

3.3 Drug Repurposing:

Drug repurposing, sometimes referred to as drug re-profiling or drug repositioning, is the process of discovering novel pharmacological applications for drugs that were previously developed to treat different medical conditions[38, 39]. This technique relies on the idea that some medications formulated for one particular indication may possess beneficial properties in treating other ailments or symptoms[1, 7].

Drug Repurposing possess several advantages such as cost-effectiveness, more efficient, time saving as compared to conventional drug development. AI assists in screening the already existing data related to safety and pharmacological activity of that drug candidate extracted during the pre-clinical trial, maintaining the safety and accuracy in identifying other beneficial effects of the medicine thereby reducing cost as well as time in conducting pre-clinical and clinical studies[1, 3, 7]. By repurposing drugs for various ailments, their life cycle can be extended, providing benefits to patients and healthcare system and offers enormous potential for expanding treatment criteria[3, 24].

3.4 AI in Drug Delivery:

Conventional methods include costly and time-consuming R&D processes to optimize delivery methods[40]. So, to overcome this problem predictive technology of AI were applied to ensure that active ingredients were available at the targeted site with maximum efficacy[4, 5, 9]. AI is quickly taking the lead in the domain of nanomedicine. Nowadays, various nano-carriers are given to patients containing nanomedicine for the treatment of different disease and only until AI is integrated with the pharmaceutical sector will this be feasible[5, 9, 41]. It primarily focuses on creating drug delivery systems that can transport active substances straight to the intended locations, such as liposomes and nanoparticles[5, 9, 29]. So, basically AI has the capability to predict the interaction of these systems within the body and provides systematic approach enabling the creation of drug delivery systems that are more precise and focused[4, 9, 29, 42].

3.5 AI in Pharmacovigilance:

The employment of AI in pharmaceutical surveillance is growing in a number of fields, such as signal management, safety operations, and target population determination[25, 26, 43]. It is a pre-requisite to understand the recent adaptation of AI in pharmacovigilance. AI has numerous applications in pharmacovigilance and patient safety, including the detection of ADEs, also known as adverse drug events and ADRs also known as adverse drug reactions, to establish drug-drug interactions, to ascertain safety reports, to simulate clinical trials, to evaluate and identify patients at high risk for ADRs, to predict side effects of drugs, to integrate prediction unreliability[25, 26]. AI also assists in diagnosing safety issues sooner than conventional methods.

3.6 Healthcare and Pharmacy Applications:

AI is flourishing in healthcare department as well as assists medical practitioners in pharmacy operations[2, 4, 11, 44]. The development of numerous technologies helps in providing effective and quick treatment which results in overall good response from patients[2, 11]. Various diagnostic methods have been developed through AI which is capable of interpreting medical images from CT and MRI scans, assisting medical professionals make accurate evaluations remotely[2, 25]. AI powered virtual assistants and chat bots provide 24*7 supports, answer medical questions and help with bridging communication gaps in remote settings[11, 25, 45]. Virtual consultations are becoming popular with the consolidation of AI in medical system ensuring continuity of care, especially for those in remote locations[2, 25, 46]. The vitals of patients could potentially be monitored through the assistance of AI integrated wearable devices[11, 24, 47, 48].

4. POTENTIAL CHALLENGES WITH POSSIBLE SOLUTIONS

Despite of having immense capabilities, it also brings several challenges while using AI tools. Serious moral concerns about safety, confidentiality, and the potential for biased outcomes are raised by the application of AI and machine learning algorithms in the medical and pharmaceutical sectors[6, 26, 49]. Programmers are therefore equipped with the skills and information necessary to handle these moral dilemmas[24, 26]. In order to utilize AI appropriately, pharmaceutical companies are facing several concerns like regulatory compliance, transparency, data quality & availability, scalability, model interpretability[6, 24, 26]. We have discussed some major points highlighting these challenges, along with proposed solutions:

4.1 Data Bias

One of the major causes of disparities in healthcare outcomes is due to biased training data reinforced by AI models[6, 26, 50]. Biased algorithms can directly influence medical care and therapeutic choices. Algorithmic bias resulting from skewed datasets may influence patient feedback replies or lead to variations in the treatments they get[6, 26]. To lessen data bias, diverse training datasets is essential. Constant monitoring and inspection of AI models could furthermore assure impartiality and credibility of offerings[51]. Apart from this, retraining of AI systems can help in recognizing and diminishing biases[24, 52].

4.2 Lack of transparency

It is very challenging to interpret the decisions of ML and AI algorithms as they are referred to as “black boxes”, which is troublesome in controlled enterprises like pharmaceuticals where liability and faith are predominant[1, 2, 7, 53]. So, there is a need for careful consideration for using AI safely and effectively. Stakeholders may lose faith in this lack of openness, necessitating strict verification procedures to ensure acceptability and authenticity[9, 24, 54]. Therefore, pharmaceutical businesses should make an investment in creating standardized and open AI and interpretable algorithms to enhance patient trust.

4.3 Data Confidentiality & Safety Hazard

Safety and confidentiality of private information are critical issues in ML and artificial intelligence[2, 7, 11, 24]. Data misuse is among the major issues because of absence of openness in AI systems where sensitive information might be used and sharing data with third parties initiate further risks[1, 2, 9]. Unauthorized access of personal information due to inadequate data retention approaches might be possible[11, 26]. To overcome this challenge, compliance with regulatory framework is needed such as the Health Insurance

Portability and Accountability Act (HIPAA) or the General Data Protection Regulation (GDPR)[9, 11, 55]. In order to successfully reduce privacy threats, enterprises will need to implement strong data governance frameworks and cutting-edge encryption technology[56].

4.4 Regulatory Hurdles

Nowadays, there is no standard framework is proved for the assessment of AI systems in drug development[1, 9, 24]. So, to ensure data privacy and patient safety, AI-driven solutions must stick to regulatory standards[7, 11]. The primary reasons behind this challenge are the frequent implementation of emerging recommendations and the differences between domestic and foreign legislation, which make compliance challenging[9, 24]. While regulating AI applications, regulatory authorities lack clarity, which raises the danger of non-compliance[57]. Therefore, in order to address these particular concerns, stakeholders and regulators must work together to create universal standards that promote evolution in addition to safety and efficacy[9, 24].

4.5 Exploiting AI in Drug Discovery

The execution of AI in pharmaceutical discovery is filled with difficulties[58]. The accessibility of appropriate data is one of the major challenges that must be considered[3, 7]. Generally, the data may be of inferior quality or inadequate and the volume of data that is available may be restricted which can influence the fidelity and trueness of the outcomes[1, 5, 24]. Multiple plans and techniques can be used to successfully deal with the constraints of using AI in discovering drugs. One approach is the utilization of EAI (Explainable AI) systems which target to come up with transparent and legitimate justifications for the estimations provided by AI algorithms[59]. Using data augmentation, which necessitates the creation of synthetic data to enhance previously established datasets, is another strategy[60]. This can improve the accuracy and validity of the results by increasing the amount, quality, and robustness of information accessible for the purpose of training machine learning algorithms.

4.6 Ongoing Monitoring and Adjustment

AI models need to be continuously monitored, updated, and improved depending on fresh data and real-world performance, they are not supposed to be static[61]. Operational complexity may result from this continuous control, requiring specialized resources, knowledgeable staff, and strong feedback loops[5, 24]. These systems are susceptible to data drift and run the danger of becoming antiquated or out of step with modern clinical procedures if we do not routinely assess them[7, 11]. Over time, this could substantially compromise their efficacy and dependability.

4.7 AI in Clinical Practice

Artificial intelligence encompasses an opportunity to transform clinical practice, but numerous limitations need to be considered to recognize its entire prospect. The shortage of healthcare information is one of these obstacles, which might lead to imprecise results[3, 7]. Data confidentiality, attainability, and protection are also potential challenges to implementing AI in patient care[62, 63]. On top of that, selecting pertinent strategy and discovering applicable medical biomarkers is important to obtaining the intended results[7, 25]. To address these issues and offer helpful answers, a multifaceted strategy, innovative data analysis methods, and the creation of highly rigid AI approaches and frameworks will be required[5, 24]. The creation of AI technologies has an impact on healthcare professions training today, emphasizing the need to recognize human lapses in fields like evidence-based medicine and critical thinking in medicine[64, 65]. Last but not least, human engagement and skill are crucial to ensuring that AI is applied appropriately and practically to satisfy clinical demands; a lack of experience could be detrimental[1, 9, 66].

4.8 Complexity in Predicting Protein Structure

Due to its intricate nature, protein structure prediction faces numerous obstacles and constraints[67]. These elements include computational complexity, efficiently negotiating the intricate configuration landscape, accurately mapping the molecular shapes, taking into account the functional adaptability of proteins, incorporating physics- based simulations, guaranteeing precise and trustworthy predictions, resolving issues with insufficient and poor data, and improving generalizability for a variety of protein structures[68, 69]. AI models generally demand a significant amount of processing power and resources, particularly deep learning architectures[69]. These models can require a lot of resources to train and refine, and not all research teams may be able to do so. This lack of interpretability makes it challenging to understand the procedure by which models land at certain predictions and to identify potential sources of error[68, 70]. With the help of data sharing and collaboration, the quality of data can be improved.

5. CONCLUSION

To sum up, this review highlights how several components of artificial intelligence are changing the current state in the pharmaceutical sector's medical care, drug development, and drug discovery. AI has demonstrated potential benefits for accelerating drug discovery by allowing analysis of increasingly large and complex datasets. In the end, it might result in precision and individualized therapy as well as the quick and economical discovery of new candidate medications and clinical trials. One example of how AI is a communal technology that enhances the entire pharmaceutical innovation pipeline is the application of AI in enhanced drug delivery systems, pharmacovigilance, clinical decision-making, and medication repurposing. The review also critically recognizes the multifaceted obstacles related to the deployment of AI. In particular, many of the challenges are ones involving data quality, algorithmic bias, interpretability, regulatory compliance and data privacy. All these challenges prevent the effective and ethical use of AI. Tackling these concerns through strong regulatory frameworks and interdisciplinary collaboration developing trustworthy and explainable AI systems will be necessary to ensure trust and long-term sustainability. Ultimately, AI represents more than an auxiliary tool; it is an evolving essential component of modern pharmaceutical research with vast potential. It has the capability to fill in glaring gaps in efficiency and innovation while clearing the path for healthcare solutions that are more patient-oriented, accurate, and economical.

ACKNOWLEDGEMENT

The Institute of Pharmacy and Paramedical Sciences, Dr. Bhim Rao Ambedkar University, Agra, provided the facilities and academic support required to complete this review, for which the authors are really grateful. Additionally, the writers would like to express their gratitude to the faculty members and guide for their helpful advice, support, and encouragement throughout the writing of this publication.

REFERENCES

[1] Sankar R, Alam MN. Artificial intelligence in drug development and delivery: Opportunities, challenges, and future directions. Journal of Angiotherapy. 2024;8(8):1-10.
[2] Aritra S, Shikha CB, Indu S. Harnessing the power of artificial intelligence in pharmaceuticals: Current trends and future prospects. Intelligent Pharmacy. 2025;3(3):181-92.
[3] Abbas F. Artificial Intelligence in Pharma: Accelerating R&D through Innovation Ecosystems. Journal of Business and Innovation. 2025;2(1):9-17.

[4] Rajesh MV, Elumalai K. The transformative power of artificial intelligence in pharmaceutical manufacturing: Enhancing efficiency, product quality, and safety. Journal of Holistic Integrative Pharmacy. 2025;6(2):125-35.

[5] Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023;15(7):1916.

[6] Saini JPS, Thakur A, Yadav D. AI driven Innovations in Pharmaceuticals: Optimizing Drug Discovery and Industry Operations. RSC Pharmaceutics. 2025.

[7] Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, et al. Artificial intelligence (AI) applications in drug discovery and drug delivery: Revolutionizing personalized medicine. Pharmaceutics. 2024;16(10):1328.

[8] Odah M. Artificial Intelligence Meets Drug Discovery: A Systematic Review on AI-Powered Target Identification and Molecular Design. 2025.

[9] Pasas-Farmer S, Jain R. From discovery to delivery: Governance of AI in the pharmaceutical industry. Green Analytical Chemistry. 2025;13:100268.

[10] Zhou Y, Wang F, Tang J, Nussinov R, Cheng F. Artificial intelligence in COVID-19 drug repurposing. The Lancet Digital Health. 2020;2(12):e667-e76.

[11] Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC medical education. 2023;23(1):689.

[12] Tiwari SK, Singh V, Kushwaha SK. A REVIEW ON: THE IMPACT OF ARTIFICIAL INTELLIGENCE IN FORMULATION DEVELOPMENT. 2024.

[13] O'Neill S. Machine learning turbocharges structural biology. Elsevier; 2022.

[14] Bhatt T, Kumar V, Pande S, Malik R, Khamparia A, Gupta D. A review on COVID-19. Artificial intelligence and machine learning for COVID-19. 2021:25-42.

[15] Suh D, Lee JW, Choi S, Lee Y. Recent applications of deep learning methods on evolution-and contact-based protein structure prediction. International Journal of Molecular Sciences. 2021;22(11):6032.

[16] Abbas M, Rassam A, Karamshahi F, Abunora R, Abouseada M. The role of AI in drug discovery. Chembiochem. 2024;25(14):e202300816.

[17] Visan AI, Negut I. Integrating artificial intelligence for drug discovery in the context of revolutionizing drug delivery. Life. 2024;14(2):233.

[18] Srivastava M, Nandan S, Zaidi A, Samani AS, Shukla V, Aslam H, et al. Artificial Intelligence Driven Applications in Analytical Chemistry, Drug Discovery, and Food Science: Advancements, Outlook, and Challenges. ChemistrySelect. 2025;10(16):e202404446.

[19] Mayr A. Deep Learning for Chemistry and Simulations/Author Andreas Mayr. 2021.

[20] Agu PC, Obulose CN. Piquing artificial intelligence towards drug discovery: Tools, techniques, and applications. Drug Development Research. 2024;85(2):e22159.

[21] Schoenmaker L, Béquignon OJ, Jespers W, van Westen GJ. UnCorrupt SMILES: a novel approach to de novo design. Journal of Cheminformatics. 2023;15(1):22.

[22] Narayanan RR, Durga N, Nagalakshmi S. Impact of artificial intelligence (AI) on drug discovery and product development. Indian J Pharm Educ Res. 2022;56:S387-S97.

[23] Malla AM, Banka AA. A Systematic Review of Deep Graph Neural Networks: Challenges, Classification, Architectures, Applications & Potential Utility in Bioinformatics. arXiv preprint arXiv:231102127. 2023.

[24] Kandhare P, Kurlekar M, Deshpande T, Pawar A. A review on revolutionizing healthcare technologies with AI and ML applications in pharmaceutical sciences. Drugs and Drug Candidates. 2025;4(1):9.

[25] Allam H. Prescribing the future: The role of artificial intelligence in pharmacy. Information. 2025;16(2):131.

[26] Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S, et al. The use of artificial intelligence in pharmacovigilance: a systematic review of the literature. Pharmaceutical medicine. 2022;36(5):295-306.

[27] Rammal DS, Alomar M, Palaian S. AI-Driven pharmacy practice: Unleashing the revolutionary potential in medication management, pharmacy workflow, and patient care. Pharmacy Practice. 2024;22(2):1-11.

[28] Shoghli A, Darvish M, Sadeghian Y. Balancing innovation and privacy: ethical challenges in AI-driven healthcare. Journal of Reviews in Medical Sciences. 2024;4(1):1-11.

[29] Tade RS, Jain SN, Satyavijay JT, Shah PN, Bari TD, Patil TM, et al. Artificial Intelligence in the Paradigm Shift of Pharmaceutical Sciences: A Review. Nano Biomedicine & Engineering. 2024;16(1).

[30] Khan MM, Shah N, Shaikh N, Thabet A, Belkhair S. Towards secure and trusted AI in healthcare: a systematic review of emerging innovations and ethical challenges. International Journal of Medical Informatics. 2025;195:105780.

[31] Soorajkumar A. Applications of Artificial Intelligence in RNA-sequencing. Artificial Intelligence and Biological Sciences: CRC Press; 2025. p. 413-20.

[32] Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular diversity. 2021;25(3):1315-60.

[33] Pun FW, Ozerov IV, Zhavoronkov A. AI-powered therapeutic target discovery. Trends in pharmacological sciences. 2023;44(9):561-72.

[34] Verma S, Pathak RK. Discovery and optimization of lead molecules in drug designing. Bioinformatics: Elsevier; 2022. p. 253-67.

[35] Wang Q, Sun B, Yi Y, Velkov T, Shen J, Dai C, et al. Progress of AI-driven drug–target interaction prediction and lead optimization. International Journal of Molecular Sciences. 2025;26(20):10037.

[36] Pandey A, Gupta SP. Personalized Medicine:(A Comprehensive Review). Oriental Journal Of Chemistry. 2024;40(4).

[37] Kumar S. Personalized medicine: the use of genetic information to tailor treatment plans to individual patients. Personal Med. 2024;1(2).

[38] Kumar S, Roy V. Repurposing drugs: An empowering approach to drug discovery and development. Drug Research. 2023;73(09):481-90.

[39] Bhatia T, Sharma S. Drug repurposing: Insights into current advances and future applications. Current Medicinal Chemistry. 2025;32(3):468-510.

[40] Heydari S, Masoumi N, Esmaeeli E, Ayyoubzadeh SM, Ghorbani-Bidkorpeh F, Ahmadi M. Artificial intelligence in nanotechnology for treatment of diseases. Journal of Drug Targeting. 2024;32(10):1247-66.

[41] Lodhi A, Jindal A, Tomar D, Kumar A, Sharma K. Artificial Intelligence in Nanocarrier Design and Drug Delivery via Nanorobotics-Based Personalised Medicine for Cancer Diagnostics and Therapy. Generative Intelligence in Healthcare: CRC Press; 2025. p. 91-124.

[42] Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. Pharmaceutics. 2022;14(4):883.

[43] Barbieri MA, Battini V, Carnovale C, Cocco M, Papoutsi DG, Heckmann NS, et al. Artificial intelligence in pharmacovigilance signal management: a review of tools, implementations, research, and regulatory landscape. Expert Opinion on Drug Safety. 2025:1-16.

[44] Stasevych M, Zvarych V. Innovative robotic technologies and artificial intelligence in pharmacy and medicine: paving the way for the future of health care—a review. Big data and cognitive computing. 2023;7(3):147.

[45] Senthilmahesh H, Nagappan MP, Shekhar S, Pandian AA, Kumar PS, Tumaati R. Advancing oncology care with AI-powered virtual assistants and chatbots: A qualitative exploration of future potential and challenges. Eurasian Journal of Medicine and Oncology. 2025;9(1):115-32.

[46] Reis TC. Artificial intelligence and natural language processing for improved telemedicine: Before, during and after remote consultation. Atencion Primaria. 2025;57(8):103228.

[47] Ghadi YY, Shah SFA, Waheed W, Mazhar T, Ahmad W, Saeed MM, et al. Integration of wearable technology and artificial intelligence in digital health for remote patient care. Journal of Cloud Computing. 2025;14(1):39.

[48] Kanakaprabha S, Kumar GG, Reddy BP, Raju YR, Rai PCM. Wearable devices and health monitoring: big data and AI for remote patient care. Intelligent data analytics for bioinformatics and biomedical systems. 2024:291-311.

[49] Tilala MH, Chenchala PK, Choppadandi A, Kaur J, Naguri S, Saoji R, et al. Ethical considerations in the use of artificial intelligence and machine learning in health care: a comprehensive review. Cureus. 2024;16(6).

[50] Smith B, Khojandi A, Vasudevan R. Bias in reinforcement learning: A review in healthcare applications. ACM Computing Surveys. 2023;56(2):1-17.

[51] Bahangulu JK, Owusu-Berko L. Algorithmic bias, data ethics, and governance: Ensuring fairness, transparency and compliance in AI-powered business analytics applications. World J Adv Res Rev. 2025;25(2):1746-63.

[52] Min A. ARTIFICIAL INTELLIGENCE AND BIAS: CHALLENGES, IMPLICATIONS, AND REMEDIES. Journal of Social Research. 2023;2(11).

[53] Chaudhary G. Unveiling the black box: Bringing algorithmic transparency to AI. Masaryk University Journal of Law and Technology. 2024;18(1):93-122.

[54] Ranjitsingh LM, Rao TS. Establish legal and regulatory standards for the testing and validation of AI systems to ensure their reliability and safety in operational environments. International Journal of System Assurance Engineering and Management. 2025;16(10):3338-53.

[55] Sangaraju VV. AI and Data Privacy in Healthcare: Compliance with HIPAA, GDPR, and emerging regulations. International Journal of Emerging Trends in Computer Science and Information Technology. 2025:67-74.

[56] Erotokritou S, Giannoulakis I, Kafetzakis E, Kaltakis K, Etenzi E, Diamantopoulos S, et al., editors. Revolutionizing Data Privacy: The ENCRYPT Project's Innovations and Applications. European, Mediterranean, and Middle Eastern Conference on Information Systems; 2024: Springer.

[57] Clement M. Ethical and Legal Risks in AI-Powered Compliance Systems. 2025.

[58] Blanco-Gonzalez A, Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, et al. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals. 2023;16(60):891.

[59] Ayesha A, Ahamed NN. Explainable artificial intelligence (EAI). Explainable Artificial Intelligence for Biomedical and Healthcare Applications. 2024:162.

[60] KUPPURAJUY S, Anand G, Choudhury A. Data Augmentation Techniques for Building Robust AI Models in Enterprise Applications. INTERNATIONAL JOURNAL. 2025;12(1):69-74.

[61] Roy P. Enhancing Real-World Robustness in AI: Challenges and Solutions. J Recent Trends Comput Sci Eng. 2024;12(1):34-49.

[62] Momani A. Implications of Artificial Intelligence on Health Data Privacy and Confidentiality. arXiv preprint arXiv:250101639. 2025.

[63] Williamson SM, Prybutok V. Balancing privacy and progress: a review of privacy challenges, systemic oversight, and patient perceptions in AI-driven healthcare. Applied Sciences. 2024;14(2):675.

[64] Lomis K, Jeffries P, Palatta A, Sage M, Sheikh J, Sheperis C, et al. Artificial intelligence for health professions educators. NAM perspectives. 2021;2021:10.31478/202109a.

[65] Simou E. The growing importance of soft skills in medical education in the ai era: Balancing humanistic care and artificial intelligence. International Medical Education. 2025;4(4):50.

[66] Knop M, Weber S, Mueller M, Niehaves B. Human factors and technological characteristics influencing the interaction of medical professionals with artificial intelligence–enabled clinical decision support systems: literature review. JMIR Human Factors. 2022;9(1):e28639.

[67] Gomes PS, Gomes DE, Bernardi RC. Protein structure prediction in the era of AI: Challenges and limitations when applying to in silico force spectroscopy. Frontiers in Bioinformatics. 2022;2:983306.

[68] Niazi SK. Critical assessment of AI-based protein structure prediction: Fundamental challenges and future directions in drug discovery. Computational and Structural Biotechnology Reports. 2025:100064.

[69] Chen L, Li Q, Nasif KFA, Xie Y, Deng B, Niu S, et al. AI-driven deep learning techniques in protein structure prediction. International journal of molecular sciences. 2024;25(15):8426.

[70] Medina-Ortiz D, Khalifeh A, Anvari-Kazemabad H, Davari MD. Interpretable and explainable predictive machine learning models for data-driven protein engineering. Biotechnology Advances. 2025;79:108495.